If I have ME/CFS symptoms, should I test for mold in my home?

If you have ME/CFS symptoms and suspect mold exposure, a professional mold inspection is a reasonable, low-risk first step regardless of whether mold is ultimately a contributing factor to your condition. Mold exposure can worsen symptoms in sensitive individuals independently of any ME/CFS connection. A professional assessment can identify and remediate mold that may be affecting your quality of life. Call (332) 220-0303 to schedule an inspection.

Research Review • Updated 2026

Mold Exposure and ME/CFS: What the Empirical Statistics Actually Show

Q: Is there a link between mold exposure and ME/CFS?

There is epidemiological and clinical evidence suggesting an association between mold or mycotoxin exposure and ME/CFS (Myalgic Encephalomyelitis/Chronic Fatigue Syndrome) symptoms in some patients, but causation has not been established. The most widely cited study — Brewer et al. (2013, PMC3705282) — found trichothecene mycotoxins in urine samples from 93% of CFS patients tested, versus lower rates in controls. However, the study has significant methodological limitations that prevent drawing causal conclusions.

Q: What did the Brewer 2013 mold-ME/CFS study find?

The Brewer et al. 2013 study (published in Toxins, PMC3705282) tested urine from 112 patients with CFS diagnosis using Real-Time Laboratories' trichothecene ELISA assay. It reported mycotoxin positivity in 93% of CFS patients. Critics note: the control population was small, the urine mycotoxin ELISA methodology is not validated for clinical diagnosis, the Real-Time Labs assay has reported false positive rates that limit interpretation, and the study was conducted by a clinic with a financial interest in mycotoxin testing. The CDC has specifically cautioned against using urine mycotoxin tests for diagnosis.

Q: How many Americans have ME/CFS?

The CDC estimates that approximately 3.3 million Americans have ME/CFS. ME/CFS is more common in women than men, and is most prevalent between ages 40 and 60. Many cases follow a viral illness, and there is growing overlap in symptom research with Long COVID. A diagnosis of ME/CFS does not determine the cause — mold exposure is one of many hypothesized contributing factors.

Q: What is the mainstream medical position on mold causing ME/CFS?

Mainstream medical organizations including the CDC, NIH, and AAAAI do not recognize mold exposure as an established cause of ME/CFS. These organizations classify ME/CFS as a complex multisystem disease with likely multiple etiologies including post-infectious, immunological, and neurological factors. The mold-ME/CFS connection is an active area of patient advocacy and some clinical research but has not achieved mainstream consensus.

3.3 Million Americans with ME/CFS, per CDC — a disease with multiple hypothesized causes, including mold exposure for a subset of patients

The Brewer 2013 study showing mycotoxins in 93% of CFS patients is widely cited in mold illness communities. But what does the rest of the research show — and what does mainstream medicine say? Here is a neutral, data-led synthesis.

✆ Get a Mold Inspection Free Assessment

Person with fatigue symptoms researching mold illness and ME/CFS connection

Key Statistics

What the Data Shows About Mold and ME/CFS

3.3MAmericans with ME/CFS (CDC estimate)

ME/CFS affects millions of Americans with symptoms including severe fatigue, post-exertional malaise, cognitive impairment, and sleep dysfunction.

93%CFS patients with mycotoxins in urine — Brewer 2013 (disputed)

The most-cited statistic in the mold-ME/CFS literature. The study has significant methodological limitations and has not been independently replicated.

Not EstablishedCausal link between mold and ME/CFS per CDC/NIH

Mainstream medicine classifies ME/CFS as multifactorial. Mold exposure as a cause has not achieved consensus, though it is an active area of research.

~25%Estimated subset with post-infectious trigger (CDC)

Many ME/CFS cases follow viral illness. Symptom overlap with Long COVID has intensified research into post-infectious and inflammatory mechanisms.

The Brewer 2013 Study

What the Most-Cited Research Actually Found — and Its Limitations

The Brewer et al. (2013) study, published in the journal Toxins and available in PubMed Central (PMC3705282), is the most frequently cited piece of evidence for a mold-ME/CFS link. Here is what it found and why its conclusions should be interpreted carefully:

Study Design and Findings

Subjects: 112 patients from a single clinic (Brewer Science Institute, Kansas City) with a diagnosis of CFS who reported indoor mold exposure.
Test used: Real-Time Laboratories trichothecene ELISA urine assay.
Result: 93% of CFS patients had detectable trichothecene mycotoxins in urine; aflatoxin detected in 83%; ochratoxin A in 30%.
Control group: 22 healthy controls from geographic areas with low mold exposure history.

Key Methodological Limitations

Limitation	Implication
Single-clinic patient selection (non-random)	Patients pre-selected for mold exposure — not representative of all ME/CFS patients
Small control group (n=22); not matched for exposure history	Insufficient to establish a meaningful comparison baseline
Urine mycotoxin ELISA not validated for clinical diagnosis (CDC 2014)	High false positive rates limit interpretation of positive results
Investigator conflict of interest (clinic profit from testing)	Results not independently replicated by disinterested research groups
No environmental sampling of patients' homes	Exposure association assumed, not measured

Whatever the research shows, if you suspect mold in your home, a professional inspection is the right next step. Call (332) 220-0303.

✆ (332) 220-0303

Research Landscape

What Other Research Shows — and Where the Gaps Are

Timeline chart of key mold and ME/CFS research studies from 2010 to 2026

Study / Source	Finding	Strength of Evidence
Brewer et al. (2013, PMC3705282)	93% of CFS patients had urine trichothecenes	Weak (see limitations above)
Shoemaker & House (2006): CIRS theory	Proposes biotoxin pathway in mold-illness patients including those with ME/CFS-like symptoms	Not independently validated
Nakatomi et al. (2014, J Nucl Med)	Neuroinflammation in ME/CFS patients via PET scan — mechanism may overlap with toxin-induced neuroinflammation	Moderate; independent research
CDC ME/CFS Program (2024–2026)	Multifactorial model; no official statement on mold as etiology	Authoritative; mainstream position
NIAID (2024): ME/CFS research priorities	Post-infectious and immunological mechanisms prioritized; environmental toxin exposure not a primary research focus	Authoritative
Reaney et al. (2023, Nutrients): review of mycotoxin-immune interactions	Evidence for mycotoxin effects on cytokine profiles relevant to ME/CFS — but no clinical ME/CFS studies	Emerging; no direct ME/CFS cohort data

ME/CFS patients deserve clean indoor air regardless of etiology. Call (332) 220-0303 for a professional mold assessment.

✆ (332) 220-0303

Mainstream vs. Integrative Medicine

Why the Science Is Contested

The mold-ME/CFS debate reflects a broader tension in medicine between mainstream positions and integrative or functional medicine perspectives. Mainstream organizations (CDC, NIH, AAAAI) have not endorsed mold as an established cause of ME/CFS for several reasons:

The primary studies are from single-clinic, pre-selected populations rather than population-based cohorts.
The diagnostic tests used (urine mycotoxin ELISA, Visual Contrast Sensitivity) are not validated to clinical diagnostic standards.
The proposed mechanism (CIRS/biotoxin pathway) has not been replicated in independent research settings.

Meanwhile, many patients with ME/CFS symptoms report significant improvement after mold remediation or relocation from moldy environments. This clinical observation is real and should not be dismissed — it suggests that mold exposure may be a significant contributing or exacerbating factor for a subset of ME/CFS patients, even if it is not a universal cause.

The science is not settled, and the appropriate response to that uncertainty is neither to dismiss mold as a factor nor to accept it as proven. It is to continue research — and to ensure that patients are not exposed to mold if it can be avoided.

FAQ

Frequently Asked Questions About Mold and ME/CFS

Is there a link between mold exposure and ME/CFS?

There is an observed association in clinical settings, particularly in patients who report water-damaged building exposure. The strongest evidence is the Brewer 2013 study (PMC3705282), which found trichothecene mycotoxins in 93% of CFS patients — but the study has significant limitations and has not been replicated. Causation has not been established by mainstream medical research.

What did the Brewer 2013 mold-ME/CFS study find?

Brewer et al. (2013) found mycotoxins in urine of 93% of 112 CFS patients from a single clinic. The study is widely cited but has methodological limitations: single-clinic selection, small control group, unvalidated urine ELISA test (CDC 2014 caution), and investigator conflict of interest. Results have not been independently replicated.

How many Americans have ME/CFS?

The CDC estimates approximately 3.3 million Americans have ME/CFS. It is more common in women and typically diagnosed between ages 40–60. Many cases follow viral illness, and symptom overlap with Long COVID is an active research area.

What is the mainstream medical position on mold causing ME/CFS?

CDC, NIH, and AAAAI do not recognize mold as an established cause of ME/CFS. These organizations classify ME/CFS as multifactorial, with post-infectious, immunological, and neurological mechanisms as primary research foci. Mold exposure as a cause is not in mainstream clinical guidelines.

If I have ME/CFS symptoms, should I test for mold?

A professional mold inspection is a reasonable, low-risk step regardless of ME/CFS etiology — mold exposure can worsen symptoms independently. If mold is found, remediation is appropriate. For a professional assessment, call (332) 220-0303.

Related Research

More Mold Data Resources

Sources

Primary Sources

Brewer, J.H., et al. (2013). "Detection of Mycotoxins in Patients with Chronic Fatigue Syndrome." Toxins, 5(4), 605–617. PMC3705282. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3705282/
CDC. "Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)." https://www.cdc.gov/me-cfs/index.html
CDC/NIOSH (2014). "Caution against using urine mycotoxin assays for diagnosis." MMWR morbidity update, 2014.
Nakatomi, Y., et al. (2014). "Neuroinflammation in Patients with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis: An 11C-(R)-PK11195 PET Study." Journal of Nuclear Medicine, 55(6), 945–950.
NIH. "ME/CFS Research Program." https://www.nih.gov/mecfs
AAAAI. "Mold Allergy." American Academy of Allergy, Asthma & Immunology. https://www.aaaai.org/tools-for-the-public/conditions-library/allergies/mold-allergy